Once-daily, oral SGLT2 inhibitor shown to reduce blood sugar and improve glycemic control as an adjunct to diet and exercise MARLBOROUGH, MA, USA I January 23, 2023 I TheracosBio today announced that the U.S. Food and Drug Administration (FDA) has approved Brenzavvy™ (bexagliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor. BRENZAVVY is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. BRENZAVVY is not recommended for patien

ADELAIDE, Australia, Jan. 22, 2023 /PRNewswire/ -- Australian biotech company Ferronova announced today it has secured a further A$11 million to progress the company's nanoparticle platform to assist surgeons to more accurately locate and remove malignant cells during treatment of gastrointestinal and brain tumors. Irish company Renew Pharmaceuticals Limited (Renew) led an A$8 million capital raise, with a further A$3 million secured via an Australian Government Co-operative Research Centers Pro

DUBLIN, Jan. 21, 2023 /PRNewswire/ -- Research and Markets The "Erythropoietin Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering. The global erythropoietin drugs market size reached US$ 9.8 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 13.8 Billion by 2027, exhibiting a CAGR of 5.87% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are cont

BEIJING, Jan. 17, 2023 /PRNewswire/ -- COVID-19 vaccines produced in China have been proven to be safe and effective by clinical trials and real-world data. The vaccines have helped save people in China and around the world, which is an irreversible accomplishment and cannot be challenged by denialists. Various options China is the only country with COVID-19 vaccines developed via multiple technical routes – they work in different ways. In addition to mRNA vaccines that uses new technology as th

SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today released unblinded Phase 1b study data of its oral main viral protease (Mpro) inhibitor, OVYDSO™ (STI-1558) in COVID patients. This Phase 1b safety, PK and efficacy study in healthy volunteers and COVID patients was conducted in China. The study (MPR-COV-101CN) is entitled: “A Randomized, Double-Blind, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic

LOS ANGELES, CA, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), a biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that NXC-201 treatment continues to demonstrate 100% complete responses in a total of 6 relapsed/refractory AL amyloidosis patients. Clinical data published December 2022 in Clinical Cancer Research (https://doi.org/10.1158/1078-0432.CCR-22-0637) d

LEXINGTON, Mass., Dec. 15, 2022 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) announced publication of a single institution retrospective cohort review of 15 patients with pediatric malignancies and invasive fungal diseases that were refractory to antifungal therapy and treated adjunctively with Leukine (sargramostim; yeast-derived, glycosylated recombinant human granulocyte-macrophage colony-stimulating factor [rhu GM-CSF]).1 Additionally, the publication included a systematic review of 50 p

RICHMOND, Calif.--(BUSINESS WIRE)-- BioAge Labs, Inc. (“BioAge”), a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that the company will host an online key opinion leader (KOL) event for analysts, investors, and other interested parties on its first-in-class apelin receptor agonist BGE-105. The event will be broadcast online on Wednesday, January 4, 2023 at 2:00 PM ET. At the virtual event,

CAMBRIDGE, Mass., Dec. 13, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the publication of a manuscript in Cancer Discovery, a journal of the American Association for Cancer Research, which describes the design and characterization of NVL-520 and details Nuvalent's approach to rationally targeting ROS1. NVL-520 is currently being studi

CAMBRIDGE, Mass., Dec. 11, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today reported new data from the ongoing extension study assessing the long-term efficacy and safety of PYRUKYND® (mitapivat) in adults with pyruvate kinase (PK) deficiency who had participated in one of the pivotal studies, ACTIVATE and ACTIVATE-T, conducted in not regularly transfused and regularly transfused adu